Entera Bio (NASDAQ:ENTX – Get Free Report) is projected to release its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 23, 2026 at 6:30 AM ET.
Entera Bio Stock Performance
ENTX opened at $1.19 on Friday. The firm has a market cap of $54.57 million, a P/E ratio of -4.76 and a beta of 1.83. The business has a 50 day moving average price of $1.43 and a 200 day moving average price of $1.93. Entera Bio has a twelve month low of $1.00 and a twelve month high of $3.22.
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on ENTX. Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a research note on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Entera Bio in a research note on Monday, February 9th. Finally, Wall Street Zen upgraded shares of Entera Bio to a “sell” rating in a report on Saturday, December 27th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.
Insider Transactions at Entera Bio
In other Entera Bio news, Director Geno J. Germano purchased 20,000 shares of the company’s stock in a transaction on Monday, March 9th. The shares were bought at an average cost of $1.30 per share, with a total value of $26,000.00. Following the transaction, the director directly owned 40,000 shares in the company, valued at approximately $52,000. This represents a 100.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders purchased 69,000 shares of company stock valued at $92,530. Company insiders own 10.38% of the company’s stock.
Institutional Investors Weigh In On Entera Bio
Hedge funds have recently modified their holdings of the business. Citadel Advisors LLC increased its position in Entera Bio by 243.0% during the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after acquiring an additional 28,322 shares during the period. HighTower Advisors LLC grew its position in Entera Bio by 137.8% in the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after purchasing an additional 25,000 shares during the last quarter. Renaissance Technologies LLC grew its position in Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after purchasing an additional 19,601 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after purchasing an additional 43,536 shares during the period. Finally, Schonfeld Strategic Advisors LLC increased its holdings in shares of Entera Bio by 5.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock worth $1,157,000 after purchasing an additional 29,629 shares during the period. 14.11% of the stock is owned by institutional investors.
About Entera Bio
Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.
The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.
See Also
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.
